To evaluate effects of AZD1446, Placebo and Donepezil in patients with Alzheimer's Disease

Study identifier:D1950C00011

ClinicalTrials.gov identifier:N/A

EudraCT identifier:2010-018273-38

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography and Event-Related Potentials in Patients with AD

Medical condition

Alzheimer´s disease

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD1446, 2.5 mg od, AZD1446, 2.5 mg od, AZD1446, 2.5 mg od, AZD1446, 2.5 mg od, AZD1446, 2.5 mg od, AZD1446, 2.5 mg od, AZD1446, 2.5 mg od, AZD1446, 2.5 mg od, AZD1446, 2.5 mg od, AZD1446, 2.5 mg od, Donepezil, Donepezil, Donepezil, Donepezil, Donepezil, Donepezil, Donepezil, Donepezil, Donepezil, Donepezil, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, AZD1446 60 mg od, AZD1446 60 mg od, AZD1446 60 mg od, AZD1446 60 mg od, AZD1446 60 mg od, AZD1446 60 mg od, AZD1446 60 mg od, AZD1446 60 mg od, AZD1446 60 mg od, AZD1446 60 mg od, AZD1446, 60 mg tid, AZD1446, 60 mg tid, AZD1446, 60 mg tid, AZD1446, 60 mg tid, AZD1446, 60 mg tid, AZD1446, 60 mg tid, AZD1446, 60 mg tid, AZD1446, 60 mg tid, AZD1446, 60 mg tid, AZD1446, 60 mg tid

Sex

All

Actual enrollment

35

Study type

Interventional

Age

55 Years - 85 Years

Date

Study Start Date: 01 Jun 2010
Primary Completion Date: 01 Mar 2011
Study Completion Date: 01 Mar 2011

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria